SCHEMBL2532011

SCHEMBL2532011

O=C1OC(=Cc2ccccc2)c2cc(Br)ccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.67
ALDH1A1 P00352 4/20 0.67
HPGD P15428 4/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
POLB P06746 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
APP P05067 1/20 0.49
RAB9A P51151 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2532009 1.00 KDM4E (0.67) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL2528750 0.86 ALDH1A1 (0.49) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL2528748 0.86 ALDH1A1 (0.49) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL10384913 0.83 KDM4E (0.75) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL10384911 0.83 KDM4E (0.75) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL10385009 0.83 KDM4E (0.75) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL10384258 0.83 KDM4E (0.75) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL8145721 0.81 KDM4E (0.73) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL4572933 0.81 KDM4E (0.73) KDM4EALDH1A1HPGDL3MBTL1TDP1
SCHEMBL29637239 0.81 KDM4E (0.73) KDM4EALDH1A1HPGDL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558459-B1 PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES ABBVIE INC (US) 2014-01-22 EP disclosed
US-8383623-B2 Phthalazin-(2H)-one inhibitors of kinases ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
EP-2558459-A1 PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-02-20 EP disclosed
WO-2011130478-A1 PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-20 WO disclosed
US-20110257187-A1 PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257187-A1 PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES CDC7, CDK17, CDK1 KDM4E 1246/4885ALDH1A1 3626/4885HPGD 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.